Precision NanoSystems, Inc. (PNI) and Entos Pharmaceuticals (Entos) today announced they have entered into a license and supply agreement whereby PNI will provide its scale-up system, technology transfer and support the GMP manufacturing of Entos’ lead candidate.
VANCOUVER, Nov. 13, 2018 /PRNewswire/ - Precision NanoSystems, Inc. (PNI) and Entos Pharmaceuticals (Entos) today announced they have entered into a license and supply agreement whereby PNI will provide its scale-up system, technology transfer and support the GMP manufacturing of Entos’ lead candidate. Entos will use the NanoAssemblr Blaze™ instrument for preclinical toxicology studies and transition to the NanoAssemblr Scale-Up system for GMP manufacturing of the drug product for clinical studies. PNI will work closely with the Entos team to provide a complete solution with instrumentation tailored to their needs, expertise and services for formulation scale-up and transition to clinical manufacturing towards phase I study. Financial terms of the agreement were not disclosed.
Entos is a healthcare biotechnology company focused on the development of next generation nucleic acid-based therapies using a proprietary Fusogenix drug delivery system. “We have been using the NanoAssemblr Benchtop instrument in our research and are excited to work with PNI as we progress our lead candidate through late stage preclinical and clinical phases of drug development” said John Lewis, CEO of Entos.
With over 250 systems placed worldwide, PNI’s NanoAssemblr platform is used by over 85 pharma and biotech companies for the development and manufacture of revolutionary therapeutics. “I see the potential in Entos’ platform to overcome challenges the field is facing in delivering gene therapies that will open the doors to treating otherwise untreatable conditions. PNI’s solution addresses manufacturing and quality challenges in developing nanomedicines and in working with Entos we are confident we will accelerate their first program through GMP manufacturing and clinical studies” said James Taylor, co-founder and CEO of PNI.
About Precision NanoSystems Inc.
Precision NanoSystems Inc (PNI) creates innovative solutions for the discovery, development and manufacture of medicines and medical research. PNI’s proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution, visit www.precisionnanosystems.com
About Entos Pharmaceuticals Inc.
Entos Pharmaceuticals is focused on the development of next generation nucleic acid-based therapies using their proprietary Fusogenix drug delivery system. Fusogenix uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi and CRISPR. For more information, visit www.entospharma.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/precision-nanosystems-and-entos-pharmaceuticals-sign-license-agreement-for-the-use-of-the-nanoassemblr-platform-for-scale-up-and-gmp-manufacturing-of-nanomedicines-300749340.html
SOURCE Precision Nanosystems
